ZBH — Zimmer Biomet Holdings Inc. price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
Key stats#
Price data
- Price
- $110.15
- YTD price return
- +22.50%
- YTD total return
- +23.48%
- Market cap
- 20.8B
- Enterprise value
- 28.2B
- Shares outstanding
- 189.3M
- 52W low
- $79.12
- 52W high
- $112.55
- From 52W high
- -2.13%
- From 52W low
- +39.22%
- 52W range
- 93%$79.12–$113
- Beta
- 0.47
Volume
- Rel volume
- 2.79×
- 30D volume
- 2.2M
- 30D $ vol
- 209.5M
Insider trading
- Insider net 1W
- none
- Insider net 1M
- none
- Insider net 3M
- −$824K
- Insider net 1Y
- −$1.6M
Form 4 transactions by trade date, as filed; latest on file 2026-09-11.
Fundamentals
- Sales (ttm)
- 8.6B
- Sales/share
- $45.29
- EPS (ttm)
- $3.95
- FCF (ttm)
- 1.6B
- FCF/share
- $8.68
- Book value/share
- $67.19
- Net margin
- 8.95%
- ROE
- 6.03%
- ROA
- 3.26%
- Debt / equity
- 0.49×
- Current ratio
- 1.46
Growth (CAGR, ttm) · 10Y
- Sales
- +6.99%+5.59%+3.73%+1.15%
- Net income
- -4.71%+17.39%-1.30%+7.76%
- FCF
- +10.70%+20.22%+5.74%+2.47%
- Shares
- -4.51%-3.25%-1.96%-0.57%
Per-share growth (CAGR, ttm) · 10Y
- EPS
- -2.38%+20.48%+0.29%+8.29%
- Sales/share
- +12.04%+9.14%+5.80%+1.78%
- FCF/share
- +15.92%+24.26%+8.00%+3.05%
- Book value/share
- +4.38%+3.92%+2.01%+3.28%
- Dividend/share
- +0.00%+0.00%+0.00%+0.21%
- Price
- +6.76%+0.43%-3.81%+1.02%
- Total return
- +7.90%+1.38%-2.95%+1.86%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 27.9×
- P/OI (ttm)
- 17.9×
- Fwd P/E
- 11.8×
- P/S (ttm)
- 2.4×
- P/B (mrq)
- 1.6×
- P/FCF (ttm)
- 12.7×
- EV/EBITDA (fy)
- 12.4×
- EV/Sales (ttm)
- 3.3×
- FCF yield (ttm)
- 7.88%
- Dividend yield (fwd)Div yield
- 0.87%
- Dividend yield (ttm)
- 0.87%
- Dividend/share (fwd)
- $0.96
- Buyback yield (realized, 1y)
- 4.51%
- Shareholder yield (realized, 1y)
- 5.46%
- Buyback yield (cash, ttm)
- 3.98%
- Shareholder yield (cash, ttm)
- 4.87%
Vs own 10Y history
- P/E
- 47th
- P/OI
- 27th
- P/S
- 14th
- P/B
- 16th
- P/FCF
- 14th
Bar = where today’s multiple sits in ZBH’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).
Performance · price returntotal return · as of 2026-11-04#
Fundamentals#
Operating income
5Y CAGR +67.6%10Y CAGR +8.9%YoY −12.4%EPS (diluted)
5Y n/m10Y CAGR +16.5%YoY −13.8%Free cash flow
5Y CAGR +8.9%10Y CAGR +8.0%YoY +33.1%TTM: operating cash flow $1.9B, capex −$241.1M
Q3 2026: operating cash flow $560M, capex −$75.8M
Shares (diluted)
5Y −4.0%10Y +4.7%YoY −3.7%Dividend per share
5Y CAGR +0.0%10Y CAGR +0.9%YoY +0.0%About Zimmer Biomet Holdings#
Zimmer Biomet Holdings Inc. is a global medical technology company focused on musculoskeletal healthcare. The company designs, manufactures, and markets orthopedic reconstructive products, including knee and hip systems, along with sports medicine, biologics, extremities, and trauma solutions. Its portfolio also includes craniomaxillofacial and thoracic products, office-based technologies, bone cement, surgical instruments, and integrated digital and robotic technologies used in orthopedic procedures. Zimmer Biomet serves healthcare professionals, hospitals, and surgical centers by providing products that support the treatment of bone, joint, and soft-tissue disorders. Headquartered in Warsaw, Indiana, Zimmer Biomet plays an important role in orthopedic care across major markets worldwide.
Warsaw, IN·17,000 employees·Medical Devices·zimmerbiomet.com·As of Oct 28, 2026
Recent filings#
- Nov 4Earnings · Earnings release — revenue $2.06B (+3% y/y) 13.5%
- Sep 11Insider sale · Thornal Kevin R (Grp Pres-Global Business) sold 5,691 shares for $529K at $92.95
- Sep 88-K · Zimmer Biomet Announces Americas Leadership Promotions to Accelerate Commercial Transformation
- Sep 4Insider sale · Phipps Chad F (See remarks below.) sold 3,000 shares for $295K at $98.35
- Aug 5Earnings · Earnings release — EPS $2.07 vs $2.01 est. (+3.0%); revenue $2.18B (+5% y/y) 2.5%
ETFs holding ZBH#
33 of the 193 ETFs ChartRow carries live hold ZBH. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).
| Fund | Name | Filed weight |
|---|---|---|
| XLV | Health Care Select Sector SPDR Fund | 0.3% |
| VHT | Vanguard Health Care ETF | 0.3% |
| RSP | Invesco S&P 500 Equal Weight ETF | 0.2% |
| VBR | Vanguard Small-Cap Value ETF | 0.2% |
| IWS | iShares Russell Mid-Cap Value ETF | 0.2% |
| VOE | Vanguard Mid-Cap Value ETF | 0.1% |
| IWR | iShares Russell Midcap ETF | 0.1% |
| VB | Vanguard Small-Cap ETF | 0.1% |
Related Healthcare#
| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +24.07% | +0.61% |
| JNJ | Johnson & Johnson | +7.92% | +3.81% |
| ABBV | AbbVie Inc. | +12.18% | +3.09% |
| MRK | Merck & Co. Inc. | +4.20% | +3.93% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | +10.08% | +1.22% |
| NVS | Novartis AG | +17.01% | +3.59% |
| TMO | Thermo Fisher Scientific Inc. | +7.84% | +1.12% |
| AMGN | Amgen Inc. | +18.69% | +3.71% |
